CAG
CTXR icon

Csenge Advisory Group’s Citius Pharmaceuticals CTXR Stock Holding History

Csenge Advisory Group’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-600
Closed -$5.51K – 707
2024
Q3 		$5.51K Hold
600
– – ﹤0.01% 705
2024
Q2 		$8.76K Hold
600
– – ﹤0.01% 662
2024
Q1 		$13.5K Hold
600
– – ﹤0.01% 705
2023
Q4 		$11.3K Hold
600
– – ﹤0.01% 659
2023
Q3 		$10.3K Hold
600
– – ﹤0.01% 635
2023
Q2 		$18K Hold
600
– – ﹤0.01% 653
2023
Q1 		$17.6K Hold
600
– – ﹤0.01% 593
2022
Q4 		$11.8K Hold
600
– – ﹤0.01% 595
2022
Q3 		$18K Hold
600
– – ﹤0.01% 606
2022
Q2 		$14K Buy
+600
New +$16.5K ﹤0.01% 566

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Csenge Advisory Group's CTXR Position: Q4 2024 in Review

Csenge Advisory Group sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 600 shares — an estimated $5.51K sold.

Csenge Advisory Group first reported a position in CTXR in Q2 2022 and held it in 10 quarters. The position peaked at $18K in Q2 2023. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Csenge Advisory Group reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Csenge Advisory Group sold 600 Citius Pharmaceuticals shares in Q4 2024, an estimated $5.51K.
  • Csenge Advisory Group first reported a position in Citius Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Csenge Advisory Group's Citius Pharmaceuticals position peaked at $18K in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Csenge Advisory Group's 13F filing for Q4 2024, filed 30 Jan 2025.